Compare AstraZeneca plc (AZN) vs Morgan Stanley (MS) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Morgan Stanley (MS) trades at $228.17, up 2.65% on the day, with strong bullish momentum from three consecutive quarterly earnings beats. The stock shows robust revenue growth, reaching $66.0B in 2025, and a net income margin of 25.56%. Technical indicators signal a bullish trend, with moving averages supporting upward movement, while RSI levels suggest mixed short-term momentum. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.

Outlook remains positive with analyst consensus favoring Buy ratings (53.85%) and a price target of $225.80, slightly below current levels. Key opportunities include continued earnings outperformance and strategic initiatives in AI and IPO leadership. Risks involve volatile cash flows, high debt levels, and macroeconomic sensitivity. Investors should weigh strong fundamentals against execution risks in a dynamic financial landscape.